Urologie (Heidelberg, Germany) · 2026
[Digital twins in uro-oncology].
Аннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smielowski Johanna, Glienke Maximilian, Mehralivand Sherif, Duwe Gregor, Chun Felix, Borgmann Hendrik, Görtz Magdalena
Аннотация
BACKGROUND: Uro-oncology is moving toward precision medicine, driven by high-dimensional longitudinal data from imaging, pathology, molecular profiling, and follow-up. However, clinical decision-making often relies on static risk scores that cannot fully capture individual disease dynamics. Digital twins aim to integrate multimodal patient data and to provide patient-specific, dynamically updated simulation models, thereby enabling "what-if" testing of interventions.
OBJECTIVE: How is a medical digital twin defined, which data foundation is available in uro-oncology, and which clinical use cases can be envisaged?
METHODS: This work comprises a narrative review including a description of the digital twin concept, a structured presentation of multimodal data (laboratory parameters, imaging, pathology, omics, long-term outcomes), and an overview of representative published applications (e.g., tumor growth reconstruction, virtual pathology, surgical 3D twins).
RESULTS: Current digital twin research in uro-oncology largely represents partial digital twins (e.g., tumor progression models, virtual assessment, patient-specific 3D surgical planning). Potential clinical value of digital twins includes dynamic risk stratification, individualized treatment planning, and adaptive follow-up strategies. Major limitations relate to data quality, interoperability, external validation, interpretability, data privacy, and regulatory requirements for clinical deployment.
CONCLUSION: Digital twins have the potential to enable a new era of predictive precision medicine in uro-oncology. Progress toward clinically actionable digital twins requires multimodal architectures, rigorous monitoring, and seamless integration into clinical workflows under robust governance and regulatory frameworks.
OBJECTIVE: How is a medical digital twin defined, which data foundation is available in uro-oncology, and which clinical use cases can be envisaged?
METHODS: This work comprises a narrative review including a description of the digital twin concept, a structured presentation of multimodal data (laboratory parameters, imaging, pathology, omics, long-term outcomes), and an overview of representative published applications (e.g., tumor growth reconstruction, virtual pathology, surgical 3D twins).
RESULTS: Current digital twin research in uro-oncology largely represents partial digital twins (e.g., tumor progression models, virtual assessment, patient-specific 3D surgical planning). Potential clinical value of digital twins includes dynamic risk stratification, individualized treatment planning, and adaptive follow-up strategies. Major limitations relate to data quality, interoperability, external validation, interpretability, data privacy, and regulatory requirements for clinical deployment.
CONCLUSION: Digital twins have the potential to enable a new era of predictive precision medicine in uro-oncology. Progress toward clinically actionable digital twins requires multimodal architectures, rigorous monitoring, and seamless integration into clinical workflows under robust governance and regulatory frameworks.